Erlotinib Impurity 90, with the CAS number 1012057-39-4, is a chemical compound associated with the pharmaceutical drug erlotinib, which is primarily used in the treatment of non-small cell lung cancer and pancreatic cancer. As an impurity, it may arise during the synthesis of erlotinib and can affect the drug's efficacy and safety profile. The characteristics of this impurity typically include its molecular structure, which may differ slightly from the parent compound, leading to variations in its chemical properties such as solubility, stability, and reactivity. Impurities like Erlotinib Impurity 90 are often characterized using techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry to ensure quality control in pharmaceutical formulations. Understanding the properties of such impurities is crucial for regulatory compliance and ensuring the safety and effectiveness of the final drug product. Additionally, the presence of impurities can influence pharmacokinetics and pharmacodynamics, making their characterization an important aspect of drug development and quality assurance.

Erlotinib Impurity 90

1012057-39-4: Erlotinib Impurity 90, with the CAS number 1012057-39-4, is a chemical compound associated with the pharmaceutical drug erlotinib, which is primarily used in the treatment of non-small cell lung cancer and pancreatic cancer. As an impurity, it may arise during the synthesis of erlotinib and can affect the drug's efficacy and safety profile. The characteristics of this impurity typically include its molecular structure, which may differ slightly from the parent compound, leading to variations in its chemical properties such as solubility, stability, and reactivity. Impurities like Erlotinib Impurity 90 are often characterized using techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry to ensure quality control in pharmaceutical formulations. Understanding the properties of such impurities is crucial for regulatory compliance and ensuring the safety and effectiveness of the final drug product. Additionally, the presence of impurities can influence pharmacokinetics and pharmacodynamics, making their characterization an important aspect of drug development and quality assurance.

CAS 1012057-39-4

Erlotinib Impurity 90

Erlotinib Impurity 90

Ref: 4Z-E-28111

Erlotinib Impurity 39

Ref: ST-EA-CP-E17049